These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30803758)

  • 1. Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug design.
    Zhang Z; Wang C; Ma L; Jiang X; Wu C; Wang Y; Jiang Y; Zheng W; Yang Y; Ma Y; Yang J
    Biochem Biophys Res Commun; 2019 Apr; 511(2):381-386. PubMed ID: 30803758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
    Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
    Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
    Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
    Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent.
    Yang H; Zhang D; Yuan Z; Qiao H; Xia Z; Cao F; Lu Y; Jiang F
    Eur J Med Chem; 2024 Mar; 267():116205. PubMed ID: 38350361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
    Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
    FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin.
    Xian J; Bu F; Wang Y; Long F; Zhang Z; Wu C; Tao Y; Wang T; Wang G
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33579052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
    Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
    Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics.
    Stec-Martyna E; Ponassi M; Miele M; Parodi S; Felli L; Rosano C
    Curr Cancer Drug Targets; 2012 Jul; 12(6):658-66. PubMed ID: 22385515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
    Kemnitzer W; Drewe J; Jiang S; Zhang H; Wang Y; Zhao J; Jia S; Herich J; Labreque D; Storer R; Meerovitch K; Bouffard D; Rej R; Denis R; Blais C; Lamothe S; Attardo G; Gourdeau H; Tseng B; Kasibhatla S; Cai SX
    J Med Chem; 2004 Dec; 47(25):6299-310. PubMed ID: 15566300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of new chromene-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods.
    Aryapour H; Dehdab M; Sohraby F; Bargahi A
    Comput Biol Chem; 2017 Dec; 71():89-97. PubMed ID: 28992456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.
    Kemnitzer W; Drewe J; Jiang S; Zhang H; Crogan-Grundy C; Labreque D; Bubenick M; Attardo G; Denis R; Lamothe S; Gourdeau H; Tseng B; Kasibhatla S; Cai SX
    J Med Chem; 2008 Feb; 51(3):417-23. PubMed ID: 18197614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
    Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
    Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based discovery and rational design of microtubule-targeting agents.
    Steinmetz MO; Prota AE
    Curr Opin Struct Biol; 2024 Aug; 87():102845. PubMed ID: 38805950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel class of tubulin inhibitors with promising anticancer activities.
    Xi J; Zhu X; Feng Y; Huang N; Luo G; Mao Y; Han X; Tian W; Wang G; Han X; Luo R; Huang Z; An J
    Mol Cancer Res; 2013 Aug; 11(8):856-64. PubMed ID: 23666368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities.
    Zhang H; Fang X; Meng Q; Mao Y; Xu Y; Fan T; An J; Huang Z
    Eur J Med Chem; 2018 Sep; 157():380-396. PubMed ID: 30099258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
    Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
    FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New substituted 4H-chromenes as anticancer agents.
    Patil SA; Wang J; Li XS; Chen J; Jones TS; Hosni-Ahmed A; Patil R; Seibel WL; Li W; Miller DD
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4458-61. PubMed ID: 22608389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
    Sharma S; Gupta MK; Saxena AK; Bedi PM
    Anticancer Agents Med Chem; 2017; 17(2):230-240. PubMed ID: 27141882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.